This single arm study will assess the efficacy and safety of loading doses of intravenous Bondronat in patients with breast cancer and malignant bone disease experiencing moderate to severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat on days 1, 2 and 3. The anticipated time on study treatment is 3 months, and the target sample size is <100 individuals.

Inclusion Criteria:

• female patients, >=18 years of age;
• breast cancer;
• bone metastases;
• moderate to severe pain;
• adequate renal function.

Exclusion Criteria:

• bisphosphonate treatment within 3 weeks of study enrollment.